TEAD4 Transcription Factor: From Developmental Regulation to Cancer Therapeutic Targets

Concept

Transcriptional Enhanced Associate Domain 4 (TEAD4) is a core member of the TEAD transcription factor family, a master regulator orchestrating mammalian early embryonic development, adult tissue homeostasis, organ regeneration and tumorigenesis. Characterized by a conserved N-terminal TEA domain with a unique cloverleaf-like conformation, TEAD4 mediates sequence-specific binding to MCAT/GTIIC cis-regulatory elements in the genome, while its C-terminal YAP/TAZ-binding domain forms a hydrophobic pocket for coactivator interaction—both domains are critical for its transcriptional activity.

Post-translational modifications (PTMs), particularly S-palmitoylation at the Cys367 residue, dynamically modulate TEAD4’s subcellular localization, protein stability and functional output, with its activity tightly governed by the Hippo signaling pathway. Aberrant TEAD4 expression and hyperactivation are closely linked to the initiation and progression of multiple malignancies, making it a promising therapeutic target for anticancer drug development. ANT BIO PTE. LTD.’s UA sub-brand, a specialist in cutting-edge recombinant proteins, offers a high-purity human TEAD4 (YBD) His Tag Protein, an indispensable research tool for elucidating TEAD4’s molecular mechanisms and advancing targeted therapeutic development.

Research Frontier

Recent breakthroughs in developmental biology and cancer research have unveiled the multifaceted and context-dependent functions of TEAD4, positioning it as a pivotal research hotspot in both basic science and translational medicine. Cutting-edge structural biology studies, via X-ray crystallography and cryo-electron microscopy, have defined the precise DNA-binding interface of TEAD4 (e.g., the histidine residue at position 51) and the structural basis of its interaction with YAP/TAZ, revealing subtle functional differences from other TEAD family members and providing a rational structural framework for drug design.

In cancer research, clinical and preclinical studies have confirmed TEAD4 as a key oncogenic transcription factor, frequently overexpressed in gastric cancer, hepatocellular carcinoma, breast cancer and colorectal cancer, and correlated with tumor aggressiveness, metastasis and poor patient prognosis. Novel research has further uncovered TEAD4’s role in tumor metabolic reprogramming (driving the Warburg effect) and tumor microenvironment remodeling, expanding our understanding of its pro-tumorigenic mechanisms beyond classical Hippo-YAP/TAZ signaling integration.

The development of TEAD4-targeted therapeutics has also entered a rapid development phase, with small-molecule inhibitors (e.g., VT104, K-975) targeting the TEAD4 palmitoylation pocket and peptide inhibitors (e.g., TED-347) disrupting TEAD4-YAP/TAZ interactions showing potent antitumor efficacy in preclinical models. Several TEAD4-targeted small molecules have now entered Phase I/II clinical trials, with TEAD4 expression emerging as a predictive biomarker for patient stratification. Additionally, innovative strategies such as PROTAC degraders, allosteric inhibitors and tissue-specific delivery systems are being explored to address the challenges of off-target toxicity and drug resistance, representing the latest research frontier in TEAD4-targeted therapy.

Research Significance

Unraveling the molecular mechanisms and biological functions of TEAD4 holds profound scientific and clinical significance across multiple research fields, with far-reaching implications for developmental biology, regenerative medicine and oncology:

1. Advancing Developmental Biology Research: TEAD4 is a master regulator of the first cell fate decision in mammalian embryos and trophectoderm specification. In-depth study of TEAD4 clarifies the molecular basis of early embryonic development and embryo implantation, providing critical insights into the pathogenesis of early pregnancy loss and offering potential therapeutic targets for reproductive disorders.
2. Guiding Regenerative Medicine Development: TEAD4 plays a key role in adult tissue regeneration (liver, skin, heart) and homeostasis maintenance, with its activity tightly regulated by mechanical signals and the Hippo pathway. Modulating TEAD4 activity in a spatiotemporal and tissue-specific manner represents a novel strategy for promoting tissue repair and regeneration, opening new avenues for the treatment of organ injury and degenerative diseases.
3. Driving Anticancer Drug Development: As a validated oncogenic transcription factor, TEAD4 integrates multiple oncogenic signaling pathways to drive tumorigenesis, metastasis and chemoresistance. Targeting TEAD4 provides a novel and promising approach for cancer therapy, especially for tumors with hyperactivated Hippo-YAP/TAZ signaling, offering new treatment options for patients with refractory malignancies such as gastric and liver cancer.
4. Enabling Precision Oncology: TEAD4 expression levels and its post-translational modification status serve as predictive biomarkers for cancer prognosis and therapeutic response. Identifying TEAD4 as a biomarker enables patient stratification for TEAD4-targeted therapies, laying the foundation for precision oncology and improving the efficacy and safety of cancer treatment.

High-quality recombinant TEAD4 protein is the foundational research tool for all the above directions, and its availability directly determines the depth and reliability of TEAD4-related mechanistic research and drug development.

Related Mechanisms and Product Applications

Core Molecular Mechanisms and Biological Functions of TEAD4

1. Structural and Post-Translational Modification Features

TEAD4’s functional activity is dictated by its unique structural architecture and dynamic post-translational modifications:

• Conserved TEA domain: A ~68-amino-acid N-terminal DNA-binding module with a cloverleaf-like 3D structure, mediating specific binding to MCAT (5'-CATTCC-3') and GTIIC (5'-GGAATG-3') elements. The H51 residue in the DNA-binding interface is critical for determining binding specificity and affinity.
• YAP/TAZ-binding domain: A C-terminal hydrophobic pocket that interacts with the Hippo pathway effectors YAP/TAZ, the key coactivators for TEAD4-mediated transcriptional activation.
• Dynamic PTMs: S-palmitoylation (predominantly at Cys367), phosphorylation, acetylation and SUMOylation dynamically regulate TEAD4’s subcellular localization, protein stability and transcriptional activity, with palmitoylation levels positively correlating with its functional output.

2. Key Biological Functions

TEAD4 exerts context-dependent and tissue-specific functions across physiological and pathological processes:

• Early embryonic development: Orchestrates the first cell fate decision in embryos and trophectoderm lineage specification by activating TE-specific genes (Cdx2, Gata3, Eomes). TEAD4 deficiency leads to mouse embryo arrest at the blastocyst stage and loss of trophoblast stem cells, mimicking human embryo implantation failure. Its activity is tightly regulated by Hippo signaling and mechanical tension in embryonic cells.
• Adult tissue homeostasis and organ regeneration: Regulates hepatocyte proliferation during liver regeneration, epidermal stem cell maintenance and differentiation in skin, and cardiomyocyte remodeling in the heart. TEAD4’s activity is modulated by the mechanical properties of the extracellular matrix, with functional diversity across different cell types (epithelial, stromal, endothelial).
• Tumorigenesis and progression: Acts as an oncogenic transcription factor by integrating Hippo-YAP/TAZ signaling with other oncogenic pathways to activate pro-tumorigenic gene programs. It enhances tumor cell migration/invasion (via MMPs and EMT factors), promotes proliferation/chemoresistance (via c-Myc, cyclin D1), drives metabolic reprogramming (Warburg effect) and remodels the tumor microenvironment (via CTGF, CYR61), contributing to tumor aggressiveness and poor prognosis.

3. TEAD4-Targeted Therapeutic Strategies

Current TEAD4-targeted intervention strategies for cancer focus on three core approaches, with ongoing development of next-generation innovative methods:

• Direct inhibition of transcriptional activity: Small molecules (VT104, K-975) competitively bind the TEAD4 palmitoylation pocket, inducing conformational changes to suppress its transcriptional function.
• Disruption of cofactor interactions: Peptide/small molecule inhibitors (TED-347) specifically block the TEAD4-YAP/TAZ protein-protein interaction, abrogating TEAD4-mediated transcriptional activation.
• Downregulation of TEAD4 expression: siRNA, shRNA and antisense oligonucleotides selectively reduce TEAD4 expression, inhibiting tumor growth and metastasis in preclinical models.
• Next-generation strategies: PROTAC degraders, allosteric inhibitors, bispecific molecules and tissue-specific delivery systems are being developed to address off-target toxicity, poor selectivity and drug resistance.

TEAD4 (YBD) His Tag Protein from ANT BIO PTE. LTD.: Core Applications and Research Value

ANT BIO PTE. LTD.’s UA sub-brand offers a high-purity Human TEAD4 (YBD) His Tag Protein (Catalog No.: UA080035), expressed in E. coli with an unconjugated His tag. This recombinant protein is produced with rigorous quality control, ensuring high purity, structural integrity and bioactivity, and serves as an essential research tool for investigating TEAD4’s molecular mechanisms and validating TEAD4-targeted therapeutic strategies.

Key Research Applications

1. Structural biology studies: Used for X-ray crystallography and cryo-electron microscopy to resolve the 3D structure of the TEAD4 YAP/TAZ-binding domain (YBD) and its complex with YAP/TAZ or small-molecule inhibitors, elucidating the molecular basis of protein-protein and protein-small molecule interactions and guiding rational drug design.
2. Protein-protein interaction assays: Applied in pull-down, co-immunoprecipitation (Co-IP), surface plasmon resonance (SPR) and biolayer interferometry (BLI) assays to verify and quantify the interaction between TEAD4 and YAP/TAZ, as well as other cofactors (e.g., VGLL, p300/CBP), and to screen for molecules that disrupt these interactions.
3. In vitro transcriptional activity assays: Utilized in reporter gene assays and in vitro transcription systems to investigate TEAD4’s transcriptional activity and the regulatory effects of PTMs (e.g., palmitoylation) and small-molecule modulators on its function.
4. High-throughput drug screening: Serves as a key reagent in high-throughput screening platforms to identify small-molecule inhibitors, peptide modulators and PROTAC degraders that target the TEAD4 YBD or inhibit TEAD4’s functional activity.
5. Antibody development and validation: Used as an immunogen and positive control for the development and validation of TEAD4-specific antibodies, supporting the detection and quantification of TEAD4 in cellular and clinical samples.
6. Mechanistic research on Hippo signaling: Employed to study the regulatory mechanism of the Hippo pathway on TEAD4 activity, and to elucidate the cross-talk between TEAD4 and other oncogenic signaling pathways in tumorigenesis.

Related Product List

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.